P2Y12 Inhibitor Monotherapy After Short DAPT in Acute Coronary Syndrome: A Systematic Review and Meta-analysis.
Mattia GalliClaudio LaudaniGiovanni OcchipintiMarco SpagnoloFelice GragnanoDomenico D'AmarioEliano Pio NavareseRoxana MehranMarco ValgimigliDavide CapodannoDominick J AngiolilloPublished in: European heart journal. Cardiovascular pharmacotherapy (2024)
In patients with ACS, P2Y12 inhibitor monotherapy after short DAPT halves bleeding without increasing ischemic events compared with standard DAPT. Ticagrelor, but not clopidogrel monotherapy, reduced MACE, NACE and mortality compared with standard DAPT, supporting its use after aspirin discontinuation. Protocol registration: This study is registered in PROSPERO (CRD42023494797).
Keyphrases
- antiplatelet therapy
- acute coronary syndrome
- percutaneous coronary intervention
- combination therapy
- open label
- st segment elevation myocardial infarction
- st elevation myocardial infarction
- cardiovascular events
- randomized controlled trial
- type diabetes
- coronary artery disease
- cardiovascular disease
- risk factors
- oxidative stress
- subarachnoid hemorrhage
- blood brain barrier
- double blind